1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063-2072.
2. Cheng W, Frei O, van der Meer D, Wang Y, O’Connell KS, Chu Y, et al. Genetic association between schizophrenia and cortical brain surface area and thickness. JAMA Psychiatry 2021;78:1020-1030.
3. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006;52:139-153.
6. Ahmed AO, Strauss GP, Buchanan RW, Kirkpatrick B, Carpenter WT. Schizophrenia heterogeneity revisited: clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. J Psychiatr Res 2018;97:8-15.
9. Hasan A, Falkai P, Wobrock T. [Early detection and treatment of schizophrenia]. MMW Fortschr Med 2010;152:53-55. German.
10. Bighelli I, Rodolico A, García-Mieres H, Pitschel-Walz G, Hansen WP, Schneider-Thoma J, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry 2021;8:969-980.
12. Vigani G, Zocchi G, Bashir K, Philippar K, Briat JF. Signals from chloroplasts and mitochondria for iron homeostasis regulation. Trends Plant Sci 2013;18:305-311.
18. Ben-Shachar D. Mitochondrial multifaceted dysfunction in schizophrenia; complex I as a possible pathological target. Schizophr Res 2017;187:3-10.
19. Whitehurst T, Howes O. The role of mitochondria in the pathophysiology of schizophrenia: a critical review of the evidence focusing on mitochondrial complex one. Neurosci Biobehav Rev 2022;132:449-464.
20. Konradi C, Öngür D. Role of mitochondria and energy metabolism in schizophrenia and psychotic disorders. Schizophr Res 2017;187:1-2.
26. Roberts RC. Mitochondrial dysfunction in schizophrenia: with a focus on postmortem studies. Mitochondrion 2021;56:91-101.
29. Fišar Z. Biological hypotheses, risk factors, and biomarkers of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2023;120:110626
31. Wang D, Cheng SL, Fei Q, Gu H, Raftery D, Cao B, et al. Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia. Psychiatry Res 2019;272:18-29.
32. Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, et al. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-results from the Juntendo University Schizophrenia Projects (JUSP). Psychiatry Res 2010;177:27-31.
34. Merritt K, Egerton A, Kempton MJ, Taylor MJ, McGuire PK. Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies. JAMA Psychiatry 2016;73:665-674.
35. Schiano C, Luongo L, Maione S, Napoli C. Mediator complex in neurological disease. Life Sci 2023;329:121986
36. Becerril S, Rodríguez A, Catalán V, Sáinz N, Ramírez B, Gómez-Ambrosi J, et al. Transcriptional analysis of brown adipose tissue in leptin-deficient mice lacking inducible nitric oxide synthase: evidence of the role of Med1 in energy balance. Physiol Genomics 2012;44:678-688.
37. Li K, Zhao B, Wei D, Wang W, Cui Y, Qian L, et al. miR‑146a improves hepatic lipid and glucose metabolism by targeting MED1. Int J Mol Med 2020;45:543-555.
42. Wang Y, Lam KS, Lam JB, Lam MC, Leung PT, Zhou M, et al. Overexpression of angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice. Mol Endocrinol 2007;21:972-986.